

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314

Status	RECRUITING
Phase	Phase 3
Sponsor	Akero Therapeutics, Inc
Enrollment	1,150 participants

Key Eligibility Criteria

Inclusion (2)

- Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH
- Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH

Exclusion (3)

- Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results
- Type 1 diabetes or unstable Type 2 diabetes
- Any current or prior history of decompensated liver disease

Locations (316 total)

Akero Clinical Study Site, Birmingham, Alabama, United States
Akero Clinical Study Site, Dothan, Alabama, United States
Akero Clinical Study Site, Chandler, Arizona, United States
... and 313 more locations